CoreWeave: Revenue Growth Narrative Collides With Balance Sheet Stress

What happened

Wall Street forecasts CoreWeave's revenue to double in 2026 and 2027, driven by massive AI demand and contracts with Meta and OpenAI. However, the company's latest filings reveal a more precarious picture: Q1 2026 net loss widened to $740M, interest expense is consuming operating income, and a new $3.1B loan (DDTL 5.0) imposes a 1.35x debt service coverage ratio test starting after September 2026. Insider selling in late May—including the CEO, directors, and multiple executives—clustered just after the lockup expiration, signaling insiders are taking profits at elevated levels. While the revenue story is compelling, the balance sheet and execution risks are material and not fully priced in at $104.

Implication

The investment thesis hinges on capacity delivery and DSCR compliance. If CoreWeave executes on schedule and operating income grows to cover interest, the stock could re-rate toward $130. However, any covenant breach or delivery delay would push equity into distressed territory below $85. Patience is warranted until at least Q2 2026 results confirm the trend.

Thesis delta

The earlier thesis focused on demand and backlog strength; the latest evidence shifts the emphasis to balance-sheet fragility and covenant risk. Insider selling and tightening financing terms suggest management is preparing for a potential liquidity event, making the risk-reward less favorable than the top-line narrative implies.